Skip to main content
PAS 2024 Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Pre-Conference Ticketed Event
Pre-Conference Ticketed Event
APA Award Winner
APA Award Winner
APS Award Winner
APS Award Winner
ASPN Award Winner
ASPN Award Winner
SPR Award Winner
SPR Award Winner
On Demand Presentation
On Demand Presentation
Poster Icons
SPR Award Winner
SPR Award Winner
Back

Robert M. Jacobson, M.D., F.A.A.P. (he/him/his)

Professor of Pediatrics
Mayo Clinic College of Medicine and Science
Rochester, Minnesota, United States

Presentation(s):

  • Impact of Multi-Level Interventions to Improve Human Papillomavirus Vaccine Uptake on Other Adolescent Vaccines Due

    Saturday, May 4, 2024
    8:30 AM – 8:45 AM ET

    Disclosure(s): 3M Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Abbott Laboratories (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Abbvie Inc. (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Adobe Inc (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Baxter Interntnl (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Becton Dickinson & Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Embecta Corp (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Hubbell Inc (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Johnson & Johnson (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Lily Eli & Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Medtronic Plc (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Merck & Co (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Moderna Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Optum Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); RPM Interntnl (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Takeda Pharma Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Zimmer Biomet Hldgs (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Zimvie (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)

  • Challenges to using EBM

    Saturday, May 4, 2024
    2:00 PM – 2:45 PM ET

    Disclosure(s): 3M Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Abbott Laboratories (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Abbvie Inc. (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Adobe Inc (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Baxter Interntnl (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Becton Dickinson & Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Embecta Corp (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Hubbell Inc (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Johnson & Johnson (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Lily Eli & Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Medtronic Plc (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Merck & Co (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Moderna Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Optum Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); RPM Interntnl (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Takeda Pharma Co (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Zimmer Biomet Hldgs (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds); Zimvie (Ongoing) (Products/Services: Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)

Email Robert